Back to News
Market Impact: 0.4
SK Biopharmaceuticals to In-License Epilepsy Drug Candidate 'Opakalim'
Source: PR Newswire
Healthcare & BiotechProduct LaunchesM&A & Restructuring
The company announced an in-licensing agreement to bring a near-commercial drug candidate directly to the U.S., targeting a commercial launch as early as 2029. Under the deal, upfront and milestone payments related to its Kv7 platform total up to $795M, with additional tiered payments referenced. The agreement supports a clearer U.S. development/commercialization path and increases potential value from the Kv7 pipeline.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.55
More News
- Paramount Closes Warner Merger in Historic Hollywood Deal
- Paramount completes $111B Warner merger, creating “Skydance” behemoth
- Paramount's hard-fought takeover of Warner Bros. Discovery closes Tuesday. Here's how we got here
- Controversial $110 billion mega-merger of Paramount and Warner Bros. finally closes
- Skydance will combine HBO Max and Paramount+ into a single streaming service
- Meta may ditch the idea of a cloud business for Muse. We think that’s a good trade